17 January 2024
17 January 2024
As the deadline nears for the government to reveal its proposed prices, pharma companies are continuing to fight regulation.
CASGEVY is indicated for usage in TDT patients aged 12 years and over.
The FDA decision is supported by data from the ADVANCE-CIDP 1 trial and the ADVANCE-CIDP 3 extension study.
Allakos’ stock price has plummeted following the announcement of two Phase II studies failing to meet their primary endpoints.
The PRGN-2012 therapeutic vaccine is intended for treating recurrent respiratory papillomatosis.
The MHRA said that males planning a family in the next year should consult their healthcare professional before valproate use.
Antimicrobial resistance is the third leading cause of death globally, with no major advances in the field in the past 50 years.
The biopharma companies will benefit from expedited timelines and scalable manufacturing expertise.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials.
Give your business an edge with our leading industry insights.
